Page
%P
2 Result(s)
-
Article
Open AccessSafety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials
Empagliflozin is a sodium-glucose co-transporter-2 inhibitor used to treat type 2 diabetes (T2D) to improve glycemic control, reduce risk of cardiovascular death in patients with T2D, and treat patients with s...
-
Article
Open AccessGuardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes
Type 2 diabetes is one of the fastest-growing health emergencies of the twenty-first century, in part due to its association with cardiovascular and renal disease. Successful implementation of evidence-based g...
